Findings from two early clinical studies suggest a new dual-action antimalarial drug candidate is well tolerated in humans. The first-in-class clinical candidate, MK7602, is being developed by WEHI ...
Janina Krumbeck, PhD, discusses the clinical advantages of next-generation sequencing over traditional culture and how this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results